pyrazines has been researched along with Anemia in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caba-Molina, M; Claver-Ferré, C; García-Marcos, SA; Gómez-Morales, M; Martín-Gómez, MA; Palacios-Gómez, ME | 1 |
| Bokhari, SW; Jones, FM | 1 |
| Aiba, K; Hatake, K; Mishima, Y; Nishimura, N; Sakajiri, S; Suzuki, K; Terui, Y; Ueda, K; Yokoyama, M | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Fu, R; Guan, J; Li, L; Liu, H; Mei, S; Qu, W; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y; Xing, L | 1 |
| Shibayama, H | 1 |
| Pallavi, R | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ | 1 |
| Balkaran, S; Daudignon, A; Fernandez, J; Hautecoeur, A; Hivert, B; Lai, JL; Leleu, X; Lepelley, P; Morel, P; Poulain, S; Rossignol, J; Roumier, C; Soenen, V; Wemeau, M | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z | 1 |
| Alexander, MP; Méndez, GP; Nasr, SH; Rennke, HG; Watson, DC | 1 |
| Morgan, G | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Colson, K; Doss, DS; Swift, R; Tariman, J; Thomas, TE | 1 |
| Aguado, B; Alegre, A; Bladé, J; Esparís-Ogando, A; Gutiérrez, N; Mateo, G; Pandiella, A; San Miguel, JF; Schenkein, D | 1 |
| Adjei, AA; Alberti, D; Alberts, SR; Binger, K; Bruzek, L; Dy, GK; Erlichman, C; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Marnocha, R; Pitot, HC; Thomas, JP; Tutsch, K; Wilding, G | 1 |
| Almuete, VI; Armstrong, DK; Baker, SD; Carducci, MA; Dinh, K; Donehower, RC; Lassiter, L; Messersmith, WA; Sullivan, RA; Wright, JJ | 1 |
| Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O | 1 |
4 review(s) available for pyrazines and Anemia
| Article | Year |
|---|---|
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous | 2011 |
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Topics: Anemia; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Monitoring; Gastrointestinal Diseases; Humans; Hypotension; Multiple Myeloma; Neutropenia; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Quality of Life; Thrombocytopenia; Water-Electrolyte Imbalance | 2004 |
6 trial(s) available for pyrazines and Anemia
| Article | Year |
|---|---|
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia | 2009 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2011 |
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; I-kappa B Proteins; Male; Middle Aged; Nausea; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vomiting | 2005 |
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Taxoids; Treatment Outcome | 2006 |
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thrombocytopenia | 2008 |
11 other study(ies) available for pyrazines and Anemia
| Article | Year |
|---|---|
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug Substitution; Flank Pain; Humans; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Renal Dialysis; Thalidomide | 2013 |
Hyperammonemic encephalopathy in multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Topics: Adult; Anemia; Antineoplastic Agents; Area Under Curve; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Disease Progression; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Tumor Lysis Syndrome | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Hepcidin and GDF15 in anemia of multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Dexamethasone; Female; Ferritins; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 15; Hemoglobins; Hepcidins; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; RNA, Messenger | 2014 |
Persistent dizziness.
Topics: Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Humans; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia | 2015 |
[Waldenström's macroglobulinemia].
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Male; Nucleosides; Phosphorylcholine; Prognosis; Protease Inhibitors; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia | 2010 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Bortezomib is an efficient agent in plasma cell leukemias.
Topics: Anemia; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Pyrazines; Thrombocytopenia; Time Factors | 2005 |